Afamitresgene autoleucel (afami-cel; Adaptimmune LLC) is an intravenously administered melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of select adults with previously treated, unresectable or metastatic synovial sarcoma.